Ibrance (Palbociclib) for Breast Cancer

Overview
Ibrance is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with metastatic breast cancer in combination with other medications. Ibrance is prescribed in cases where tumors are estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative. Ibrance is also referred to by its drug name, palbociclib.

Ibrance is a member of a class of drugs called kinase inhibitors, and it is designed to inhibit the growth of cells. Ibrance is believed to work by slowing the growth of tumors.

How do I take it?
Prescribing information states that Ibrance is taken once daily.

Ibrance comes in capsule form.

Side effects
The FDA-approved label for Ibrance lists common side effects including low blood cell counts, infections, fatigue, nausea, stomach flu, hair loss, diarrhea, rash, vomiting, decreased appetite, weakness, and fever.

Rare but serious side effects listed for Ibrance include severe infections and pulmonary embolisms (blood clots in the lungs).

For more information about this treatment, visit:

Ibrance — Pfizer
https://www.ibrance.com